Trademark: 97760513
Word
QUAISAR DRUG DESIGN PLATFORM
Status
Pending
Status Code
661
Status Date
Thursday, January 18, 2024
Serial Number
97760513
Mark Type
4000
Filing Date
Thursday, January 19, 2023

Trademark Owner History
ROIVANT DISCOVERY, INC. - 1st New Owner Before Publication
Roivant Sciences GmbH - Original Applicant

Classifications
9 Downloadable and recorded computer software for providing, analyzing and generating reports; downloadable and recorded computer software for data processing; electronic apparatus, electronic equipment, downloadable and recorded software, programs and systems for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and/or transmission of data, images and information; downloadable and recorded computer software for database integration; downloadable and recorded software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; downloadable and recorded software for genetic assessment and identification of diseases, health status and metrics, and gene mutations for scientific, medical, diagnostic, treatment, and research purposes; downloadable and recorded software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical data and images, to analyze data, and to develop pharmaceutical products and chemical compounds; downloadable and recorded software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement
42 Scientific and technological services and research and design in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; analyzing of technical scientific and pharmaceutical research data by computers; Pharmaceutical drug discovery services; pharmaceutical and biotechnology research and development services; drug discovery services; design and development of pharmaceutical preparations and medicines; research and development in the field of drug discovery; conducting scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; analyzing scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; providing scientific, pharmaceutical and agrochemical database research services; scientific and pharmaceutical artificial intelligence research services to identify molecules and compounds for drug discovery and chemical development; bioinformatics services, namely, using the combination of biology, computer science, information engineering, mathematics and statistics to analyse and interpret biological data; computer assisted molecule design; scientific and biological research, namely, identification of biological targets, networks and pathways; biological research and analysis; pharmaceutical research and development services; computer aided diagnostic for scientific research purposes; computer aided scientific screening services for scientific research purposes; contract scientific research services in support of scientific research and development of pharmaceutical preparations; software as a service (SaaS) featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; software as a service (SaaS) for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software as a service (SaaS) for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement
"DRUG DESIGN PLATFORM"

Trademark Events
Jan 18, 2024
Teas/Email Correspondence Entered
Jan 17, 2024
Correspondence Received In Law Office
Jan 17, 2024
Teas Response To Office Action Received
Oct 16, 2023
Application Extension Granted/Receipt Provided
Oct 16, 2023
Application Extension To Response Period - Received
Oct 4, 2023
Automatic Update Of Assignment Of Ownership
Jul 17, 2023
Notification Of Non-Final Action E-Mailed
Jul 17, 2023
Non-Final Action E-Mailed
Jul 17, 2023
Non-Final Action Written
May 31, 2023
Assigned To Examiner
Feb 8, 2023
New Application Office Supplied Data Entered
Jan 23, 2023
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24